Document is current
Any future updates will be listed below
-
Authors
Simpson, Rebecca C.
Shanahan, Erin R.
Scolyer, Richard A.
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
- License Information
-
More Information
Article History
Accepted: 4 July 2023
First Online: 24 July 2023
Competing interests
: R.A.S. has acted as a consultant and/or adviser to Amgen, Bristol-Myers Squibb, Evaxion, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, MetaOptima Technology Inc, Merck Sharp & Dohme, Myriad Genetics, NeraCare Inc, Novartis, Provectus Biopharmaceuticals Australia and Qbiotics. G.V.L. has acted as a consultant and/or adviser to Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, OncoSec, PHMR Ltd, Pierre Fabre, Provectus, Qbiotics and Regeneron. The other authors declare no competing interests.
